The global Interventional Cardiology Devices Market is on track to reach a value of USD 37.29 billion by 2032, according to projections from SNS Insider. The market was valued at USD 22.23 billion in 2024, reflecting a compound annual growth rate (CAGR) of 6.68% during the period from 2025 to 2032.
In the United States, the market is anticipated to expand from USD 5.69 billion in 2024 to USD 9.38 billion by 2032, showcasing a CAGR of 6.46%. This growth is largely attributed to the rising demand for minimally invasive procedures, advancements in stent and catheter technology, and the increasing prevalence of cardiovascular diseases (CVDs).
The landscape of patient care is changing as precision-guided, imaging-assisted, and robotic interventions become more prevalent, offering benefits such as reduced recovery times, shorter hospital stays, and improved outcomes for patients. Additionally, the expansion of cardiac catheterization laboratories in regions like Asia-Pacific and Latin America, along with increased healthcare investments, is further propelling the growth of this market.
In 2024, the segment for coronary stents accounted for approximately 35.32% of the market share, driven by their widespread application in percutaneous coronary interventions (PCI) and the popularity of drug-eluting stents. The PCI segment was the dominant revenue generator, capturing over 55.76% of the market, due to its effectiveness in treating coronary artery disease.
Looking ahead, the peripheral vascular intervention (PVI) segment is expected to experience the fastest growth, with a projected CAGR of 7.33% from 2024 to 2032. This is largely due to the increasing incidence of peripheral artery disease and the growing geriatric and diabetic populations.
The drug-eluting stent segment led the market with a revenue share of about 60.52% in 2024, thanks to its ability to significantly reduce restenosis rates and improve long-term outcomes. The biodegradable stent segment is also poised for impressive growth, with an estimated CAGR of 7.75% over the forecast period, due to advancements in bioresorbable materials.
Hospitals and clinics represented the largest end-user segment in 2024, accounting for around 60.22% of the market share. This dominance can be attributed to the presence of advanced healthcare infrastructure, skilled cardiologists, and a favorable reimbursement environment.
Regionally, the Asia-Pacific market is projected to grow at the fastest rate of 7.07% during the forecast period, driven by an increasing prevalence of cardiovascular diseases, an aging population, and rising rates of diabetes and obesity. North America held the largest market share at approximately 38.80% in 2024, supported by well-established medical facilities and a high incidence of CVDs.
Recent innovations in the field include the launch of the SYNERGY XD drug-eluting stent by Boston Scientific in Europe and the introduction of the IN.PACT Admiral drug-coated balloon by Medtronic in the United States.
For further details, the complete analysis of the Interventional Cardiology Devices Market can be accessed through this report.
